论文部分内容阅读
我们采用第二代ＥＩＡ法检测了８２例再生障碍性贫血（ＡＡ）患者血清丙型肝炎病毒抗体（抗ＨＣＶ），结果显示，输血治疗的ＡＡ患者抗ＨＣＶ阳性率６９．４％（４３／６２），显著高于未输血患者（ｐ＜０．０１），慢性ＡＡ与急性ＡＡ抗ＨＣＶ阳性率无明显差别（Ｐ＞０．０５）。ＡＡ患者输血后丙型肝炎（ＰＴＨＣ）发生率３３．９％（２１／６２），其中急性ＡＡ６８．８％（１１／１６），慢性ＡＡ２１．７％（１０／４６），前者显著高于后者（Ｐ＜０．０１）。抗ＨＣＶ阳性患者发生ＰＴＨＣ组与未发生ＰＴＨＣ组输血量、血红蛋白水平、白细胞数的差别无统计学意义。抗ＨＣＶ阳性患者ＡＡ有效率明显低于抗ＨＣＶ阴性患者（ｐ＜０．０５）。ＡＡ患者发生ＰＴＨＣ以急性、黄疸型多见，合并ＰＴＨＣ后易出血、感染。本研究结果表明，ＰＴＨＣ已成为ＡＡ的重要合并症，ＡＡ合并ＰＴＨＣ采用中西医结合治疗可取得较好疗效。
We used the second-generation EIA method to detect serum hepatitis C virus antibody (anti-HCV) in 82 patients with aplastic anemia (AA). The results showed that the anti-HCV positive rate of transfusion-treated AA patients was 69.4% (43/62 ) Was significantly higher than that of patients without blood transfusion (p <0.01). There was no significant difference in the positive rate of anti-HCV between chronic AA and acute AA (P> 0.05). The incidence of hepatitis C (PTHC) in patients with AA was 33.9% (21/62) after transfusions, including acute AA 68.8% (11/16) and chronic AA 21.7% (10/46), the former was significantly higher than the latter (P <0.01). There was no significant difference in blood transfusion volume, hemoglobin level and white blood cell count between PTHC group and non-PTHC group in anti-HCV positive patients. The effective rate of AA in anti-HCV positive patients was significantly lower than that in anti-HCV negative patients (p <0.05). AA patients with acute PTHC, jaundice more common, bleeding after PTHC merger, infection. The results of this study show that PTHC has become an important complication of AA, AA combined with PTHC with traditional Chinese and Western medicine treatment can achieve better results.